We entered into a letter agreement with Mr. Cloonan in March 2017, and he assumed the role of Chief
Business Officer in April 2017. The agreement entitled Mr. Cloonan to an initial base salary of $440,000 (which has increased to $468,652 as of March 31, 2019). Mr. Cloonan received a signing bonus of $125,000. Mr. Cloonan is
also eligible for performance-based variable cash compensation in an amount determined by the Compensation Committee (with a target of 40% of his base salary as of March 31, 2019), based upon attainment of corporate and individual goals, as
agreed between Mr. Cloonan and the Chief Executive Officer.
We entered into a letter agreement with Ms. Cook in August 2015, and she assumed
the role of Senior Vice President and General Counsel in September 2015. The agreement entitles Ms. Cook to an initial base salary of $360,000 (which has increased to $428,558 as of March 31, 2019). Ms. Cook received a signing bonus
of $50,000. Ms. Cook is also eligible for performance-based variable cash compensation in an amount determined by the Compensation Committee (with a target of 40% of her base salary as of March 31, 2019), based upon attainment of corporate
and individual goals, as agreed between Ms. Cook and the Chief Executive Officer and as approved by the Compensation Committee.
We entered into a
letter agreement with Dr. Robichaud in September 2011, and he assumed the role of Chief Scientific Officer in November 2011. The agreement entitled Dr. Robichaud to an initial base salary of $300,000 (which has increased to $427,231 as of
March 31, 2019). Dr. Robichaud received a signing bonus, with $65,000 paid out during his first month of employment and an additional $50,000 paid on the
one-year
anniversary of his employment.
Dr. Robichaud is eligible for performance-based variable cash compensation in an amount determined by the Compensation Committee (with a target of 40% of his base salary as of March 31, 2019), based upon attainment of corporate and
individual goals, as agreed between Dr. Robichaud and the Chief Executive Officer and as approved by the Compensation Committee.
None of the named
executive officers participate in or have account balances in qualified or
non-qualified
defined benefit plans sponsored by us as of December 31, 2018, and, as a result, there is not a pension benefits
table included in this Proxy Statement.
Nonqualified Deferred Compensation
None of the name executive officers participate in or have account balances in nonqualified defined contribution or nonqualified deferred compensation plans
maintained by us as of December 31, 2018, and, as a result, there is not a nonqualified deferred compensation table included in this Proxy Statement.
Payments Provided upon Termination without Cause and Change in Control
We have entered into severance and change in control agreements, or severance agreements, with each of Dr. Jonas, Ms. Iguchi, Mr. Cloonan,
Ms. Cook and Dr. Robichaud. Pursuant to their severance agreements, each of Dr. Jonas, Ms. Iguchi, Mr. Cloonan, Ms. Cook and Dr. Robichaud is eligible to receive certain payments and benefits in the event that such
officers employment is terminated by us without cause (as defined in the applicable severance agreement), or in the event that such officer terminates his or her employment with good reason (as defined in the applicable
severance agreement).
In the event that Dr. Jonas, Ms. Iguchi, Mr. Cloonan, Ms. Cook or Dr. Robichaud terminates his or her
employment with good reason or is terminated without cause, other than in the event of a change of control, he or she is eligible to receive 12 months of base salary continuation and 12 months of COBRA continuation medical
benefits subsidized by us, provided that the terminated executive officer executes, and does not revoke, a separation agreement and release of us and our affiliates.
Pursuant to their severance agreements, in the event that any of Dr. Jonas, Ms. Iguchi, Mr. Cloonan, Ms. Cook or Dr. Robichaud
terminates his or her employment with good reason or is terminated without cause within the 12 month period following a change in control (as defined in the applicable severance agreement), such officer
36